 This study will evaluate the safety and tolerability of durvalumab MEDI4736 tremelimumab in combination with first line chemotherapy regimens in patients with locally advanced or metastatic solid tumors: ovarianperitonealfallopian tube cancer, squamous cell carcinoma of the head and neck SCCHN, triple negative breast cancer TNBC, small cell lung carcinoma SCLC, and gastricgastro-esophageal junction GEJ cancer, pancreatic ductal adenocarcinoma PDAC and esophageal squamous cell carcinoma ESCC. 